Company Performance Metrics
Maria-Grazia Roncarolo: Co-Founder, President, and Head of R&D- David de Vries: Co-Founder & COO
Tr1X is a biotechnology company that specializes in the development of allogeneic engineered regulatory T (Treg) and chimeric antigen receptor Treg (CAR-Treg) cell therapies aimed at treating autoimmune and inflammatory diseases. Tr1X's lead investigational therapy, TRX103, is an allogeneic engineered T cell product derived from CD4+ cells
sourced from healthy donors, designed to mimic the function of Type 1 regulatory T (Tr1) cells. The U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for TRX103, allowing the initiation of clinical trials for treatment-refractory Crohn’s Disease. Additionally, Tr1X has received an $8 million grant from the California Institute for Regenerative Medicine (CIRM) to support the TRX103 Phase 1/2a clinical trial for Graft-Versus-Host Disease.
